Why the study?
Heart failure with preserved ejection fraction represents a growing public health problem with few drugs successfully improving clinical outcomes, necessitating research into new therapeutic strategies targeting underlying pathological mechanisms.
This review highlights emerging pharmacological and mechanical strategies targeting novel pathophysiological mechanisms in HFpEF.
Heart failure with preserved ejection fraction (HFpEF) is a growing public health problem in nearly 50% of patients with heart failure. Therefore, research on new strategies for its diagnosis and management has become imperative in recent years. Few drugs have successfully improved clinical outcomes in this population. Therefore, numerous attempts are being made to find new pharmacological interventions that target the main mechanisms responsible for this disease. In recent years, pathological mechanisms such as cardiac fibrosis and inflammation, alterations in calcium handling, NO pathway disturbance, and neurohumoral or mechanic impairment have been evaluated as new pharmacological targets showing promising results in preliminary studies. This review aims to analyze the new strategies and mechanical devices, along with their initial results in pre-clinical and different phases of ongoing clinical trials for HFpEF patients. Understanding new mechanisms to generate interventions will allow us to create methods to prevent the adverse outcomes of this silent pandemic.
No takes yet. Share an insight, caveat, or question.
Parra-Lucares et al. (2022) conducted a review in Heart failure with preserved ejection fraction (HFpEF). New pharmacological strategies and mechanical devices was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: